Compare HITI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HITI | AMRN |
|---|---|---|
| Founded | 2009 | 1989 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.8M | 339.8M |
| IPO Year | N/A | 1993 |
| Metric | HITI | AMRN |
|---|---|---|
| Price | $2.89 | $14.03 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | $6.13 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 551.9K | 83.6K |
| Earning Date | 01-28-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $410,600,094.00 | $226,733,000.00 |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $29.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.18 | N/A |
| 52 Week Low | $1.64 | $7.08 |
| 52 Week High | $4.06 | $20.90 |
| Indicator | HITI | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 32.77 |
| Support Level | $2.56 | $13.64 |
| Resistance Level | $2.98 | $14.67 |
| Average True Range (ATR) | 0.13 | 0.71 |
| MACD | 0.06 | -0.15 |
| Stochastic Oscillator | 89.22 | 11.96 |
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, Famous Brandz, and others. The company's reportable operating segments are; Bricks and mortar which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada followed by the United States of America, and other international markets.
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.